Sudan Loganathan Analyst PerformanceManaging Director at StephensSudan Loganathan is a stock analyst at Stephens in the medical sector, covering 15 publicly traded companies. Over the past year, Sudan Loganathan has issued 23 stock ratings, including strong buy, buy, and hold recommendations. While full access to Sudan Loganathan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sudan Loganathan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings28 Last 1 YearsBuy Recommendations85.71% 24 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution28RatingsDistribution of strong buy, buy, hold, and sell ratings by Sudan Loganathan.RatingPercentageCount Strong Buy7.1%2 ratings Buy78.6%22 ratings Hold14.3%4 ratings Sell0.0%0 ratingsOut of 28 total stock ratings issued by Sudan Loganathan at Stephens, the majority (78.6%) have been Buy recommendations, followed by 14.3% Hold and 7.1% Strong Buy.Best & Worst CallsBest Call00.0%NRIXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.3% of companies on NASDAQ14 companiesNYSE6.7% of companies on NYSE1 companySudan Loganathan, an analyst at Stephens, currently covers 15 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Sudan Loganathan of Stephens specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE11 companies73.3%MED - DRUGS2 companies13.3%PHARMACEUTICAL PREPARATIONS1 company6.7%MED INSTRUMENTS1 company6.7% About Sudan LoganathanSudan Loganathan, PhD is a Managing Director and equity research analyst covering the Biotechnology sector, with a focus on oncology, immunology and rare diseases. Sudan joined Stephens in May 2023, following previous roles as an equity research associate or senior associate at Cantor Fitzgerald, H.C. Wainwright and RBC Capital Markets following large-cap pharma, specialty pharma and biotechnology sectors. Sudan received his B.S. in Biomedical Sciences from Murray State University in 2013 and his Ph.D. from Meharry Medical College and Vanderbilt University Medical Center in Neuroscience, Cancer Biology and Pharmacology in 2018.Follow on LinkedIn Sudan Loganathan's Ratings History at Stephens Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsATNMActinium Pharmaceuticals3/31/2026Reiterated Rating$0.99$5.00Overweight$0.0000.00% ROIIMNMImmunome3/4/2026Lower Price Target$21.54$30.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics3/2/2026Boost Price Target$91.35$100.00Overweight$0.0000.00% ROIAPGEApogee Therapeutics12/16/2025Initiated Coverage$74.78$95.00Overweight$0.0000.00% ROIAPGEApogee Therapeutics12/16/2025Upgrade$77.35Strong-Buy$0.0000.00% ROIKYMRKymera Therapeutics12/11/2025Boost Price Target$89.89$110.00Overweight$0.0000.00% ROICADLCandel Therapeutics12/8/2025Reiterated Rating$5.33$15.00Overweight$0.0000.00% ROIPYXSPyxis Oncology11/24/2025Boost Price Target$4.80$8.00Overweight$0.0000.00% ROIIMNMImmunome11/17/2025Boost Price Target$17.14$33.00Overweight$0.0000.00% ROIARVNArvinas11/10/2025Boost Price Target$10.63$15.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DCTHDelcath Systems11/5/2025Lower Price Target$8.75$18.00Overweight$0.0000.00% ROICNTACentessa Pharmaceuticals10/28/2025Initiated Coverage$24.46$35.00Overweight$0.0000.00% ROICADLCandel Therapeutics10/28/2025Upgrade$5.60Strong-Buy$0.0000.00% ROICNTACentessa Pharmaceuticals10/28/2025Initiated Coverage$25.00$35.00Overweight$0.0000.00% ROICADLCandel Therapeutics10/27/2025Initiated Coverage$5.40$15.00Overweight$0.0000.00% ROICCCCC4 Therapeutics9/22/2025Reiterated Rating$3.16$6.00Overweight$0.0000.00% ROIARVNArvinas9/18/2025Lower Price Target$7.61$14.00Overweight$0.0000.00% ROICCCCC4 Therapeutics9/15/2025Upgrade$2.66$6.00Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences9/9/2025Reiterated Rating$23.39$45.00Overweight$0.0000.00% ROINRIXNurix Therapeutics7/10/2025Reiterated Rating$13.18$30.00Overweight$0.0000.00% ROIEXELExelixis6/24/2025Upgrade$43.37$60.00Overweight$0.0000.00% ROIDCTHDelcath Systems6/23/2025Reiterated Rating$13.47$25.00Overweight$0.0000.00% ROIBPMCBlueprint Medicines6/3/2025Downgrade$127.79$135.00Hold$0.0000.00% ROIELEVElevation Oncology3/24/2025Reiterated Rating$0.30$1.00Equal Weight$0.0000.00% ROIELEVElevation Oncology3/7/2025Reiterated Rating$0.51$5.00Overweight$0.0000.00% ROIEXELExelixis2/12/2025Reiterated Rating$35.11$29.00Equal Weight$00.0000.00% ROIEXELExelixis1/27/2025Reiterated Rating$33.37$29.00Equal Weight$00.0000.00% ROINRIXNurix Therapeutics1/21/2025Reiterated Rating$19.84$31.00Overweight$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
